JGC
AVDL

J. Goldman & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

J. Goldman & Co’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-86,100
Closed -$1.13M – 460
2024
Q3 		$1.13M Sell
86,100
-133,700
-61% -$2.04M 0.03% 279
2024
Q2 		$3.09M Buy
+219,800
New +$3.58M 0.09% 212
2024
Q1 		– Sell
-24,000
Closed -$339K – 415
2023
Q4 		$339K Buy
+24,000
New +$282K 0.01% 279
2016
Q1 		– Sell
-80,000
Closed -$977K – 290
2015
Q4 		$977K Buy
+80,000
New +$1.25M 0.1% 180

Other funds holding AVDL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

J. Goldman & Co's AVDL Position: Q4 2025 in Review

J. Goldman & Co sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 94,867 shares — an estimated $1.45M sold.

J. Goldman & Co first reported a position in AVDL in Q4 2014 and held it in 25 quarters. The position peaked at $13.9M in Q2 2016. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • J. Goldman & Co reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 94,867 Avadel Pharmaceuticals shares in Q4 2025, an estimated $1.45M.
  • J. Goldman & Co first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 25 quarters.
  • J. Goldman & Co's Avadel Pharmaceuticals position peaked at $13.9M in Q2 2016.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.